Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Singapore
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Camzyos (mavacamten) is a cardiac myosin inhibitor. It is indicated for the treatment of:
It is a prescription cardiology medicine and must be used under the supervision of a qualified cardiologist, with regular echocardiogram monitoring as required by its REMS program (see Warnings section).
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Boxed Warning — Risk of Heart Failure: Camzyos reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required before starting treatment and regularly during therapy. Camzyos should not be started in patients with LVEF below 55%, and treatment should be interrupted if LVEF falls below 50% at any visit or if heart failure symptoms occur or worsen.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Camzyos (mavacamten) capsules may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Camzyos (mavacamten capsules) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Camzyos is not commercially marketed in India.
However, patients in India can legally access Camzyos through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.
Camzyos received US FDA approval in 2022, ensuring full transparency throughout the process.
Camzyos can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) can source Camzyos from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. Camzyos capsules should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and are handled under temperature-controlled shipping conditions throughout transit. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Camzyos cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Camzyos through regulated import pathways, with delivery arranged to the treating hospital based on a valid cardiologist's prescription.
A major cardiac care hub with leading cardiology centers, Mumbai coordinates access to advanced HCM therapies like Camzyos for eligible patients.
As part of the Delhi NCR region, the city has a strong concentration of cardiology specialists, making it a key location for accessing advanced cardiac treatments.
With a growing network of multispecialty cardiac hospitals, Bangalore supports access to Camzyos through structured import pathways guided by treating cardiologists.
Home to several reputed cardiology centers, Chennai facilitates access to Camzyos for patients with obstructive hypertrophic cardiomyopathy.
A growing hub for cardiac care, Hyderabad supports coordinated access to Camzyos for eligible patients under specialist supervision.
Eastern India's leading cardiac centers in Kolkata coordinate Camzyos access for patients with HCM.
With an expanding base of cardiology clinics, Pune facilitates timely access to Camzyos under prescription.
Gujarat's leading cardiac hospitals support regulated access to Camzyos for eligible patients.
Kerala's healthcare network, including major cardiac centers in Kochi, coordinates access to advanced cardiology therapies like Camzyos.
Serving North India, Chandigarh's cardiology centers facilitate access to Camzyos for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Camzyos through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Camzyos under cardiologist care.
Odisha's growing cardiology sector supports patient access to Camzyos.
As a referral hub for the North-East, Guwahati facilitates access to Camzyos for patients across the region.
Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
